Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

4D Molecular Therapeutics

4DMT is focused on the discovery and development of targeted, customized and proprietary next-generation AAV gene therapy products for use in patients with severe genetic diseases with high unmet medical need. Our robust discovery platform, termed Therapeutic Vector Evolution, empowers us to create customized gene delivery vehicles to deliver genes specifically to any tissue or organ in the body, by optimal clinical routes of administration, at lower doses and with resistance to pre-existing antibodies. These proprietary and targeted products allow us to treat both rare genetic diseases and complex large market diseases. 4DMT is creating a diverse and deep product pipeline through its own internal 4D products, as well as partnered programs.

Key Contact
Name
David Kirn
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
09/06/18 $90,000,000 Series B ArrowMark Partners
Berkeley Catalyst Fund
Chiesi Ventures
CureDuchenne Ventures
Janus Henderson Investors
MiraeAsset Financial Group
Pappas Capital
Perceptive Advisors
Pfizer Venture Investments
Ridgeback Capital Management
The Biotechnology Value Fund
Viking Global Investors
undisclosed


Featured Reading